FDA picks Denali, Neurogene and more for rare disease program
04 Jun 2024 //
FIERCE BIOTECH
Grace Science, FDA START For NGLY1 Gene Therapy GS-100, 2nd Patient Treated
03 Jun 2024 //
BUSINESSWIRE
Grace Science Announces First Patient Treated in Phase 1/2/3 Trial of GS-100
05 Mar 2024 //
BUSINESSWIRE
Grace Announces Clearance of IND to Initiate a Phase 1/2/3 Trial of AAV9 NGLY1
07 Nov 2023 //
BUSINESSWIRE